This Standard Operating Procedure (SOP) describes the methodology for performing immunohistochemistry staining using paraffin-embedded or frozen tissue, or cytology samples
Method Article
Immunohistochemistry with Ventana
https://doi.org/10.1038/protex.2019.023
This work is licensed under a CC BY 4.0 License
This protocol has been posted on Protocol Exchange, an open repository of community-contributed protocols sponsored by Nature Portfolio. These protocols are posted directly on the Protocol Exchange by authors and are made freely available to the scientific community for use and comment.
posted 15 Jul, 2019
You are reading this latest protocol version
This Standard Operating Procedure (SOP) describes the methodology for performing immunohistochemistry staining using paraffin-embedded or frozen tissue, or cytology samples
The use of tissue staining to facilitate observation under the microscope began with Hematoxylin–Eosin in the XIX century.
Histoenzymology appeared in the early part of the century, a technique which consists of using the remains of un-fixed tissue, such as studies with DPNase and ATPase in muscle diseases.
The first immunohistochemistry was performed with fluorescent antibodies in fresh tissue, such as those used today in a range of skin and kidney diseases.
By contrast, immunoenzymatic methods (peroxidase, avidin-biotin) which permit amplification of the chromogen signal favoured the use of formalin-fixed, paraffin-embedded tissue. Synthetic polymers are now used to amplify the signal (Envision, Powervision).
Immunohistochemistry is essential for anatomopathological diagnosis of diseases, particularly neoplasms.
For immunohistochemistry to be completely useful, strict quality control standards, both internal - of the performing lab - and external, must be adhered to during tissue fixation, indications for use, reading and evaluation of results.
Immunohistochemistry may be performed in tissue from both biopsy and autopsy, normally formalin-fixed, paraffin-embedded, as well as in cytologies. Fixation is essential since poor fixing means the result obtained is unreliable.
Immunohistochemistry is a powerful diagnostic and investigative tool which provides information that complements routine morphological evaluation of tissue. The use of immunohistochemistry to study cellular markers that define specific phenotypes has provided valuable diagnostic, prognostic and predictive information on disease stage and biology. The use of antibodies for molecular study of tissue in the field of pathology has made it necessary to adapt and perfect immunohistochemistry assays, especially using fixed tissue. The history of immunohistochemistry has therefore been one of continual striving to improve the sensitivity of detection of rare antigenic targets with the ultimate goal of integrating tissue into the analysis.
Due to the morphology provided by formalin-fixed paraffin-embedded tissues, this has become the method of choice for the majority of clinical and investigative studies. The method of staining antibodies with peroxidase was introduced in 1968 and was the first to be used in paraffin-embedded tissue. These pioneering studies using labelled enzymes instead of fluorescent colourings paved the way for the development of modern immunohistochemistry methods, such as automation.
Depending on the type of sample to be studied by immunohistochemistry, this must be treated in order to ensure penetration by aqueous solutions, expose blocked epitopes and block all non-specific bindings, reagent groups etc. To do so, the sample is hydrated and heat-treated in EDTA buffers (ph8) (See section 5.7.1). Once antigenic retrieval has been performed, the sample is incubated with the primary specific antigen, then with the second and then retrieved in order to observe the presence or absence of the protein of interest.
ALK antibody (Ref. 06679072001 ROCHE)
AXL antibody (Ref. NBP1-83073 NOVUS BIOLOGICALS)
Beta-catenin antibody (Ref. 05269016001)
BIM antibody (Ref. AB32158 ABCAM)
BTRCP antibody (Ref. AB137674 ABCAM)
CAM 5.2 antibody (Ref. 06478425001 ROCHE)
c-MET antibody (Ref. 05571219001 ROCHE)
Cromogranin antibody (Ref. 05267056001 ROCHE)
E-Cadherin antibody (Ref. 05973872001 ROCHE)
ER antibody (Ref. 05278406001 ROCHE)
Ki67 antibody (Ref. 05278384001 ROCHE)
LKB1 antibody (Ref. AB15095 ABCAM)
FGFR1 antibody (Ref. AB824 ABCAM)
FGFR2 antibody (Ref. WH2263M1 SIGMA)
MERTK antibody (Ref. HPA036196 ATLAS ANTIBODIES)
N-cadherin antibody (Ref. AB18203 ABCAM)
PD-1 antibody (Ref. 07099029001 ROCHE)
PD-L1 antibody (Ref. M4420 ROCHE)
pEGFR antibody (Ref. 3777S CELL SIGNALING)
pFGFR1 antibody (Ref. AB111124 ABCAM)
ROS1 antibody (Ref. 3287 CELL SIGNALING)
Synaptophysin antibody (Ref. 06433324001 ROCHE)
TTF-1 antibody (Ref. 06640613001 ROCHE)
Vimentin antibody (Ref. 05278139001 ROCHE)
Antibody diluent (Ref. 05261899001 ROCHE)
DPX (mounting media) (Ref.1.019979.0500 MERCK)
Absolute ethanol (Ref. 1. 00986. 2500 MERCK)
96% ethanol (see SOP-001)
70% ethanol (see SOP-001)
Ventana Optiview Amplification Kit (OV) (Ref. 06396518001)
OV Amplifier
OV H2O2 Amplification
OV Multimer Amplification
Ventana Bluing (Ref. 05266726001)
Ventana Hematoxylin (Ref. 05266769001)
Ventana CC1 ULTRA (Ref. 05424569001)
Ventana EZ PREP 10X (Ref. 05279771001)
Ventana Ultraview Kit (UV) (Ref. 05269806001)
UV DAB Inhibitor
UV HRP Multimer
UV DAB Chromogen
UV DAB H2O2
UV DAB Copper
OV Peroxidase Inhibitor
OV HQ universal linker
OV HRP Multimer
OV DAB
OV H2O2
OV Copper
Ventana LCS ULTRA (Ref. 05424534001)
Ventana Reaction Buffer (Ref. 05353955001)
Ventana SSC (Ref. 05353947001)
Xylene (Ref. 8. 08697. 1000 MERCK)
Slide staining basket (Ref. 14047533750 LEICA MICROSYSTEMS)
Staining tray (Ref.14047533659 LEICA MICROSYSTEMS)
Glass cover (Ref. BB024040A1 MENZEL-GLASER)
Knives/blades (Ref. 152200 MICROM)
Labels (Ref. 05247829001 ROCHE)
Standard quality gloves.
10, 20, 100, 200 and 1000 μl automatic pipette tips (Nucleid Acid and Nuclease Free; Non-Pyrogenic; Certified Pure).
Printer for labels (Ref. 05250889001 ROCHE)
Superfrost ultra plus glass slide 1*72un (Ref. 5421659001 ROCHE)
Ventana Prep KIT 502 (50 test) (Ref. 05275822001 ROCHE)
Ventana Prep KIT 512 (50 test) (Ref. 05275938001 ROCHE)
Vortex
Microcentrifuge
Brush
VENTANA BenchMark ULTRA (ROCHE)
Hood
Freezer
Oven
Microscope
Fridge
10, 20, 100, 200 and 1000 μl automatic pipettes
-AUTOSTAINER XL automatic stainer (LEICA)
5.7.1 STAINING
This assay is performed in the Oncology Laboratory in the:
Molecular Pathology Room: Microtomy
Main laboratory: Immunohistochemistry staining
Extraction Room: Drying out and mounting
Notes on the protocol
Antigen retrieval is performed by warm incubation in EDTA buffers (ph8). The main problem with this method is that some epitopes are irreversibly damaged by heat, something which is more likely to occur if the tissue is poorly fixed. Special adhesive layers are used to avoid tissue cuts becoming unstuck (See section 5.5.2). The method of antigen retrieval, incubation time and concentration of the antibody vary according to the staining used (see table below). This is performed at 95ºC, except for PDL1 which is carried out at 100ºCX.
Microtomy
Cutting is carried out as described in SOP-003. Immunohistochemistry staining
Enter the cases to be processed with the VENTANA BenchMark ULTRA (ROCHE) and print the labels.
Check the jars of reagents and residues (fill or empty as necessary).
Ventana CC1 ULTRA
Ventana EZ PREP 10X
Ventana LCS ULTRA
Ventana Reaction Buffer
Ventana SSC
Fill the rest with distilled water
If full, empty the waste jar into the appropriate residue jar
Steps
Heat the carrier at 60ºC and incubate for 4 minutes
Wash 3 times with EZ PREP solution at 72ºC to remove the paraffin
Heat the glass slide to 36ºC and perform 3 washes with reaction buffer
Apply a drop of UV DAB inhibitor and incubate for 4 minutes to stop the endogenous peroxidase from working
Perform 2 washes with reaction buffer
Apply a drop of the primary antibody and incubate for a specific period depending of the antibody (see table) Ultraview Kit (UV)
Perform 2 washes with reaction buffer
Apply a drop of UV HRP Multimer and incubate for 8 minutes
Perform 2 washes with reaction buffer
Apply a drop of UV DAB Chromogen and a drop of UV DAB H2O2 and incubate for 8 minutes
Perform 1 wash with reaction buffer
Apply a drop of UV DAB Copper and incubate for 4 minutes
Perform 1 wash with reaction buffer
Apply a drop of Hematoxylin and incubate for 4 minutes, except for the LKB1 antibody which is incubated for 8 minutes
Perform 2 washes with reaction buffer
Apply a drop of Bluing and incubate for 4 minutes
Perform 2 washes with reaction buffer Optiview Kit (OV)
Perform 3 washes with reaction buffer
Apply a drop of OV HQ universal linker, incubate for 12 minutes and perform 3 washes with reaction buffer
Apply a drop of OV HRP Multimer, incubate for 12 minutes and perform 2 washes with reaction buffer
Apply a drop of OV Amplifier and a drop of OV Amplification H2O2 and incubate for 12 minutes
Perform 2 washes with reaction buffer
Apply a drop of OV Amplification Multimer and incubate for 8 minutes
Perform 3 washes with reaction buffer
Apply a drop of OV H2O2 and a drop of OV DAB, incubate for 8 minutes and perform 1 wash with reaction buffer
Apply a drop of OV Copper, incubate for 4 minutes and perform 1 wash with reaction buffer
Apply a drop of Hematoxylin, incubate for 4 minutes and perform 2 washes with reaction buffer
Apply a drop of Bluing, incubate for 4 minutes and perform 2 washes with reaction buffer Notes: Steps 21-23 refer to the Optiview Amplification Kit and are not performed for the pFGFR1 antibody.
Drying out and mounting samples
Once the sample is determined to be evaluable, the scheme to be followed for antibodies is:
a) According to the proportion of stained tumoral cells
b) According to the intensity of neoplastic cells stained:
0 (lack of intensity)
1 (weak staining)
2 (moderate staining)
3 (intense staining)
The pathologist first determines whether the tumoral cells can be distinguished from non-neoplastic areas in the tissue to be examined, or whether the analysis cannot be carried out due to artefacts, fixation or processing incidents.
Evaluable: Tumoral cells can be distinguished from non-tumoral areas and an anatomical pathology report can be provided with an appropriate diagnosis.
Not evaluable: Tumoral cells cannot be distinguished from non-tumoral areas and an anatomical pathology report with an appropriate diagnosis cannot be provided.
Once the sample is determined to be evaluable, the scheme to be followed for antibodies is:
a) According to the proportion of stained tumoral cells
b) According to the intensity of neoplastic cells stained:
0 (lack of intensity)
1 (weak staining)
2 (moderate staining)
3 (intense staining)
labeled antibody method: A study of pituitary glands of the rat. Nakene PK. J Histochem Cytochem 1968; 16: 557-60.
An immunoglobulin-enzyme bridge method for localizing tissue antigens. Mason TE, et al. J Histochem Cytochem 1969; 17: 563-9.
The unlabeled antibody-enzyme method of immunohistochemistry. Preparation and properties of soluble antigen- antibody complex (horseradish peroxidase-antihorse-radish peroxidase) and its use in identification of spirochetes. Sternberger LA, et al. J Histochem Cytochem 1970; 18: 315.
Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. Hsu SM, Raine L, et al. J Histochem Cytochem 1981; 29: 577-80.
Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. Ponder Ba and Wilkinson MM J. Histochem Cytochem 1981; 29: 981-4.
An unlabeled antibody method using glucose oxidase-antiglucose oxidase complexes (gag): a sensitive alternative to immunoperoxidase for the detection of tissue antigens. Clark Ca et al. J. J Histochem Cytochem 1982; 30: 27-34
Comparison of the cytoplasmic antigens of leprosy-derived corynebacteria and some mycobacteria. Harboe NMG and Ingild A. Scand J Immunol 1983; 17: 497-506.
Enhanced polymer detection system for immunohistochemistry. Heras A, Roach CM, Key ME. Lab Invest 1995; 72:165
AXL mediates TRAIL resistance in esophageal adenocarcinoma. Hong J, Belkhiri A. Neoplasia. 2013 Mar; 15(3):296-304.
Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Giles KM, et al. Mol Cancer Ther. 2013 Sep 11.
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Ben-Batalla I, et al. Blood. 2013 Oct 3; 122(14):2443-2452.
Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Chen PX, Li QY, Yang Z. Ann Diagn Pathol. 2013 Oct;17(5):425-9.
Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration. Duijkers FA, et al. Gene. 2013 May 25;521(1):62-8..
Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Sawabu T, et al. 2007 Feb;46(2):155-64
Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis. Zhang Y, et al. Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):179-88.
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Linger RM , et al. Oncogene. 2013 Jul 18; 32(29):3420-31.
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma. Pinato DJ, et al. Br J Cancer. 2013 Feb 19; 108(3):621-8.
The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Paccez JD, et al. Int J Cancer. 2013 May 3.
The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Meyer AS, et al. Sci Signal. 2013 Aug 6;6(287):ra66.
Apoptosis and autophagy: bim as a mediator of tumour cell death in response to oncogene-targeted therapeutics. Gillings AS, Balmanno K, CM, M, SJ. Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Cambridge, UK. 2009 Nov 276:6050-62.
None
Flowchart IHC Flowchart
This protocol has been posted on Protocol Exchange, an open repository of community-contributed protocols sponsored by Nature Portfolio. These protocols are posted directly on the Protocol Exchange by authors and are made freely available to the scientific community for use and comment.
posted 15 Jul, 2019
You are reading this latest protocol version
© Research Square 2022